Tags

Type your tag names separated by a space and hit enter

[Impact of endocannabinoid system in modulation of cardiometabolic risk factors].
Vnitr Lek. 2006 Jun; 52(6):615-8.VL

Abstract

Endocannabinoid system, the complex of specific cannabinoid receptors (CB1 and CB2 subtypes) and their endogenous agonistic ligands (endocannabinoids) plays, besides others, an important role in the central and peripheral regulation of food intake, fat accumulation, and lipid and glucose metabolism. Alterations of these functions are associated with endocannabinoid system hyperactivity. The cannabinoid receptor CB1 antagonist rimonabant normalizes the over activated endocannabinoid system which contributes to the regulation of energy homeostasis, and improves lipid and glucose metabolism--decreases body weight, waist circumference, intra-abdominal obesity and triglycerides, increases HDL-C, improves insulin sensitivity according to HOMA index. Results of the international multicentric clinical trials confirm that rimonabant is well tolerated and show antiatherogenic effects (increased adiponectin, decreased marker of inflammation CRP and improvement of LDL profile) as well as decreased percentage of subjects with NCEP/ATPIII (National Cholesterol Education Program Adult Treatment Panel III) defined metabolic syndrome. Thus, the CB1 cannabinoid receptor antagonist rimonabant is suggested to be a prospective drug decreasing cardiometabolic risk factors.

Authors+Show Affiliations

Farmakologický ustav Lékarské fakulty MU, Brno. sulcova@med.muni.cz

Pub Type(s)

Journal Article
Review

Language

cze

PubMed ID

16871766

Citation

Sulcová, A. "[Impact of Endocannabinoid System in Modulation of Cardiometabolic Risk Factors]." Vnitrni Lekarstvi, vol. 52, no. 6, 2006, pp. 615-8.
Sulcová A. [Impact of endocannabinoid system in modulation of cardiometabolic risk factors]. Vnitr Lek. 2006;52(6):615-8.
Sulcová, A. (2006). [Impact of endocannabinoid system in modulation of cardiometabolic risk factors]. Vnitrni Lekarstvi, 52(6), 615-8.
Sulcová A. [Impact of Endocannabinoid System in Modulation of Cardiometabolic Risk Factors]. Vnitr Lek. 2006;52(6):615-8. PubMed PMID: 16871766.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Impact of endocannabinoid system in modulation of cardiometabolic risk factors]. A1 - Sulcová,A, PY - 2006/7/29/pubmed PY - 2006/10/4/medline PY - 2006/7/29/entrez SP - 615 EP - 8 JF - Vnitrni lekarstvi JO - Vnitr Lek VL - 52 IS - 6 N2 - Endocannabinoid system, the complex of specific cannabinoid receptors (CB1 and CB2 subtypes) and their endogenous agonistic ligands (endocannabinoids) plays, besides others, an important role in the central and peripheral regulation of food intake, fat accumulation, and lipid and glucose metabolism. Alterations of these functions are associated with endocannabinoid system hyperactivity. The cannabinoid receptor CB1 antagonist rimonabant normalizes the over activated endocannabinoid system which contributes to the regulation of energy homeostasis, and improves lipid and glucose metabolism--decreases body weight, waist circumference, intra-abdominal obesity and triglycerides, increases HDL-C, improves insulin sensitivity according to HOMA index. Results of the international multicentric clinical trials confirm that rimonabant is well tolerated and show antiatherogenic effects (increased adiponectin, decreased marker of inflammation CRP and improvement of LDL profile) as well as decreased percentage of subjects with NCEP/ATPIII (National Cholesterol Education Program Adult Treatment Panel III) defined metabolic syndrome. Thus, the CB1 cannabinoid receptor antagonist rimonabant is suggested to be a prospective drug decreasing cardiometabolic risk factors. SN - 0042-773X UR - https://www.unboundmedicine.com/medline/citation/16871766/[Impact_of_endocannabinoid_system_in_modulation_of_cardiometabolic_risk_factors]_ DB - PRIME DP - Unbound Medicine ER -